Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Irinotecan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 known ✓ | P11387 | 6/20 | 0.77 |
| ▸ | GLA | P06280 | 2/20 | 0.99 |
| ▸ | GAA | P10253 | 2/20 | 0.99 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.99 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.99 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.99 |
| ▸ | MMP1 | P03956 | 1/20 | 0.99 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.99 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.99 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.99 |
| ▸ | ACHE | P22303 | 1/20 | 0.99 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.99 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.99 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.97 |
| ▸ | LMNA | P02545 | 1/20 | 0.97 |
| ▸ | HPGD | P15428 | 1/20 | 0.97 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.97 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.97 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Irinotecan SCHEMBL1650846 | 0.99 | GLA (0.97) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL29356918 | 0.99 | GLA (1.00) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL12313065 | 0.99 | GLA (1.00) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL29367581 | 0.99 | GLA (1.00) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL4034 | 0.99 | GLA (1.00) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL131381 | 0.99 | GLA (1.00) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL13420262 | 0.99 | GLA (1.00) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL19534323 | 0.99 | GLA (1.00) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL1780951 | 0.99 | GLA (0.96) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL1501478 | 0.99 | GLA (0.99) | GLAGAASLC22A2SLC22A1SLC22A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090148506-A1 | LIPOSOMAL FORMULATIONS COMPRISING SECONDARY AND TERTIARY AMINES AND METHODS FOR PREPARING THEREOF | CELATOR PHARMACEUTICALS, INC. | 2009-06-11 | — | — | US | disclosed |
| EP-1976485-A2 | LIPOSOMAL FORMULATIONS COMPRISING SECONDARY AND TERTIARY AMINES AND METHODS FOR PREPARING THEREOF | Celator Pharmaceuticals, Inc. (US) | 2008-10-08 | — | — | EP | disclosed |
| WO-2007076117-A2 | LIPOSOMAL FORMULATIONS COMPRISING SECONDARY AND TERTIARY AMINES AND METHODS FOR PREPARING THEREOF | CELATOR PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | WO | disclosed |